This is a routine executive promotion with no new financial data or guidance. Monitor upcoming quarterly results for TONMYA launch metrics and revenue trajectory, which will be the key driver for TNXP.
Price Chart
Executive Summary
Tonix Pharmaceuticals promoted Thomas Englese from EVP of Commercial Operations to Chief Commercial Officer, effective immediately. This is a routine internal promotion recognizing his leadership in the launch of TONMYA for fibromyalgia, but contains no new financial data, guidance, or material business developments.
Key Facts
- Thomas Englese promoted to Chief Commercial Officer, effective September 8, 2026
- Englese had served as EVP of Commercial Operations since September 2024
- He continues to oversee sales, marketing, and market access for TONMYA (fibromyalgia), Zembrace SymTouch, and Tosymra (migraine)
- This is Tonix's first Chief Commercial Officer appointment
- No financial figures, guidance, or material business changes were disclosed in the filing
Financial Impact
No financial impact disclosed in the filing
Risk Factors
- No new financial data to assess commercial traction of TONMYA launch
- Forward-looking statements about TONMYA expansion are unquantified and not actionable
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-041689 |
| Document: form8-k.htm | 0001493152-26-041689 |
| Document: 0001493152-26-041689-index-headers.html | 0001493152-26-041689 |
| Document: 0001493152-26-041689-index.html | 0001493152-26-041689 |
| Document: 0001493152-26-041689.txt | 0001493152-26-041689 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $5.73 | awaiting T+20 | — | $5.36 (−6.46%) |
Oct 15, 2026 12d ago | 8-K | $6.42 | awaiting T+20 | — | $5.36 (−16.51%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.36 (+33.58%) |
Sep 22, 2026 5w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.36 (−49.39%) |
Sep 8, 2026 7w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.36 (−59.27%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.36 (−57.43%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.36 (−57.43%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.36 (−49.77%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.36 (−48.31%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.36 (−54.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers